Branden J Stansley et al.
The Journal of pharmacology and experimental therapeutics, 351(2), 440-447 (2014-09-13)
L-Dopa (l-3,4-dihydroxyphenylalanine) is the precursor to dopamine and has become the mainstay therapeutic treatment for Parkinson's disease. Chronic L-dopa is administered to recover motor function in Parkinson's disease patients. However, drug efficacy decreases over time, and debilitating side effects occur